191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

Saved in:

Bibliographic Details
Published in	Journal of thoracic oncology Vol. 11; no. 4; pp. S139 - S140
Main Authors	Peters, S., Antonia, S., Goldberg, S.B., Heymach, J.V., Kim, E.S., Nakagawa, K., Papadimitrakopoulou, V., Mukhopadhyay, P., McIntosh, S., Rizvi, N.A.
Format	Journal Article
Language	English
Published	United States Elsevier Inc 01.04.2016
Online Access	Get full text

Loading…

More Information
ISSN:	1556-0864 1556-1380
DOI:	10.1016/S1556-0864(16)30300-8